James Paul Scopa

CIK: 0001356950

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (25.0%)

Compensation grants

Other (G, F, J, C, D, …)9 (75.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

ALGS

Aligos Therapeutics, Inc.

Director

ADVM

Adverum Biotechnologies, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (12 total)

ALGS
Aligos Therapeutics, Inc.
Jun 25, 2026
Award(A)
Stock Option (Right to Buy)
Direct
5.9K shares-
ADVM
Adverum Biotechnologies, Inc.
Dec 9, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
4.7K shares-
ADVM
Adverum Biotechnologies, Inc.
Dec 9, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
4.5K shares-
ADVM
Adverum Biotechnologies, Inc.
Dec 9, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
3K shares-
ADVM
Adverum Biotechnologies, Inc.
Dec 9, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
4K shares-
ADVM
Adverum Biotechnologies, Inc.
Dec 9, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
4K shares-
ADVM
Adverum Biotechnologies, Inc.
Dec 9, 2025
Tender Offer(U)
Direct
10.3K shares-
ADVM
Adverum Biotechnologies, Inc.
Dec 9, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
10.5K shares-
ADVM
Adverum Biotechnologies, Inc.
Dec 9, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
10.5K shares-
ADVM
Adverum Biotechnologies, Inc.
Dec 9, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
4K shares-
ALGS
Aligos Therapeutics, Inc.
Jun 25, 2025
Award(A)
Stock Option (Right to Buy)
Direct
5.9K shares-
ADVM
Adverum Biotechnologies, Inc.
Jun 17, 2025
Award(A)
Stock Option (Right to Buy)
Direct
10.5K shares-

		Type	Shares	Price		Ownership
Jun 25, 2026	ALGS Aligos Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	5,860	-	-	Direct
Dec 9, 2025	ADVM Adverum Biotechnologies, Inc.	Disposition(D) Stock Option (Right to Buy)	4,666	-	-	Direct
Dec 9, 2025	ADVM Adverum Biotechnologies, Inc.	Disposition(D) Stock Option (Right to Buy)	4,500	-	-	Direct
Dec 9, 2025	ADVM Adverum Biotechnologies, Inc.	Disposition(D) Stock Option (Right to Buy)	3,000	-	-	Direct
Dec 9, 2025	ADVM Adverum Biotechnologies, Inc.	Disposition(D) Stock Option (Right to Buy)	4,000	-	-	Direct
Dec 9, 2025	ADVM Adverum Biotechnologies, Inc.	Disposition(D) Stock Option (Right to Buy)	4,000	-	-	Direct
Dec 9, 2025	ADVM Adverum Biotechnologies, Inc.	Tender Offer(U)	10,333	-	-	Direct
Dec 9, 2025	ADVM Adverum Biotechnologies, Inc.	Disposition(D) Stock Option (Right to Buy)	10,520	-	-	Direct
Dec 9, 2025	ADVM Adverum Biotechnologies, Inc.	Disposition(D) Stock Option (Right to Buy)	10,450	-	-	Direct
Dec 9, 2025	ADVM Adverum Biotechnologies, Inc.	Disposition(D) Stock Option (Right to Buy)	4,000	-	-	Direct
Jun 25, 2025	ALGS Aligos Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	5,860	-	-	Direct
Jun 17, 2025	ADVM Adverum Biotechnologies, Inc.	Award(A) Stock Option (Right to Buy)	10,450	-	-	Direct

1-12 of 12 transactions

About Scopa James Paul

Scopa James Paul (SEC CIK 0001356950) files insider reports with the SEC as Director of Aligos Therapeutics, Inc. (ALGS) and Director of Adverum Biotechnologies, Inc. (ADVM).

Signal8 holds 4 ownership filings by Scopa James Paul, all Form 4s, filed between Jun 20, 2025 and Jun 29, 2026. Those filings report 12 transactions, from Jun 17, 2025 to Jun 25, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Scopa James Paul's filings is in SOUTH SAN FRANCISCO, CA.

Recent filings by Scopa James Paul

Jun 25, 2026: Grant or award of ALGS derivative securities (Form 4, code A).
Dec 9, 2025: Disposition to issuer transactions of ADVM derivative securities (5 lines, Form 4, code D).
Dec 9, 2025: Tender of shares transaction of ADVM shares (Form 4, code U).
Dec 9, 2025: Disposition to issuer transactions of ADVM derivative securities (3 lines, Form 4, code D).
Jun 25, 2025: Grant or award of ALGS derivative securities (Form 4, code A).

Other insiders filing for Aligos Therapeutics, Inc. (ALGS)

How to read Form 4 transaction codes